Breaking News

Vetter Successfully Commercializes 8 Customer Drug Products

Brought eight customer drugs to market after supporting them through the development phases.

Author Image

By: Charlie Sternberg

Associate Editor

Vetter, a contract development and manufacturing organization (CDMO), has successfully commercialized eight customer drug products as of the end of 2023, supported by the comprehensive portfolio of the Vetter Development Service during their drug development phases.   The drug products that reached the world market are used in oncology and to treat autoimmune and cardiovascular diseases, among others. Their nature and administration vary widely, ranging from emergency medications to long-term ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters